2013-08-23
fosun pharma announces selection of quintiles for first global post-marketing pharmacovigilance outsourcing project
with its philosophy of continuous innovation in researching and manufacturing to international standards, fosun pharma, china’s leading healthcare company, is dedicated to providing safe and good quality products to improve healthcare.
guilin pharma, a subsidiary company of fosun pharma, recently signed an agreement with quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, to provide international post-marketing pharmacovigilance for guilin pharma’s antimalarial products.
under the agreement, quintiles began providing those post-marketing pharmacovigilance services for guilin pharma last month.
“we believe our guilin pharma subsidiary is the first chinese domestic pharmaceutical company to start monitoring and management of a marketed drug internationally,” said mr. li xianlin, senior vice president of fosun pharma and chairman of the fosun pharmaceutical industrial management committee.
guilin pharma is the only chinese-local finished drug manufacturer approved by the world health organization (who) for its antimalarial products. artesun, the original innovative brand product of guilin pharma, is recognized and recommended by who in over 20 malaria endemic countries as the gold standard for severe malaria treatment, and helps to save thousands of african children annually.
guilin pharma of fosun pharma acknowledges the importance of detection, assessment, understanding and prevention of adverse effects or any other drug-related problems in the product’s life-cycle, and always dedicates itself to improve the safety and efficacy of its products.
“we are pleased to have quintiles, the world’s leading provider of biopharmaceutical services, to provide these post-marketing pharmacovigilance services,” mr. li xianlin said. “we believe quintiles’ network, its safety and pharmacovigilance professional team, as well as its advanced data management system, will help our chinese local company go the extra mile and achieve full internationalism from development and manufacturing to commercialization.”
guilin pharma, a subsidiary company of fosun pharma, recently signed an agreement with quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, to provide international post-marketing pharmacovigilance for guilin pharma’s antimalarial products.
under the agreement, quintiles began providing those post-marketing pharmacovigilance services for guilin pharma last month.
“we believe our guilin pharma subsidiary is the first chinese domestic pharmaceutical company to start monitoring and management of a marketed drug internationally,” said mr. li xianlin, senior vice president of fosun pharma and chairman of the fosun pharmaceutical industrial management committee.
guilin pharma is the only chinese-local finished drug manufacturer approved by the world health organization (who) for its antimalarial products. artesun, the original innovative brand product of guilin pharma, is recognized and recommended by who in over 20 malaria endemic countries as the gold standard for severe malaria treatment, and helps to save thousands of african children annually.
guilin pharma of fosun pharma acknowledges the importance of detection, assessment, understanding and prevention of adverse effects or any other drug-related problems in the product’s life-cycle, and always dedicates itself to improve the safety and efficacy of its products.
“we are pleased to have quintiles, the world’s leading provider of biopharmaceutical services, to provide these post-marketing pharmacovigilance services,” mr. li xianlin said. “we believe quintiles’ network, its safety and pharmacovigilance professional team, as well as its advanced data management system, will help our chinese local company go the extra mile and achieve full internationalism from development and manufacturing to commercialization.”